Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research progress on treatment of liver cirrhosis induced by hepatitis C

( views:247, downloads:304 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 1

DOI:: 10.3760/cma.j.issn.1674-2397.2014.01.021

Key Word:: 肝炎,丙型;肝硬化;抗病毒治疗;持续病毒学应答;Hepatitis C;Liver cirrhosis;Antiviral therapy;Sustained virological response

Abstract： Pegylated interferon plus ribavirin is still the standard treatment for hepatitis C,but the efficacy is often restricted by adverse events.HCV genotypes,viral dynamics during early treatment and gene polymorphism may be useful in predicting the efficacy of antiviral treatment.Several strategies have emerged to improve outcomes including low accelerating dose regimen (LADR) and prevention of complications.Direct antiviral drugs have been already used for HCV genotype 1 patients,and demonstrated improved efficacy.Besides,inhibitors and vitamin D may also be applied in antiviral therapy to improve the efficacy.This article reviews efficacy predictors,standard therapy,strategies and research on new medicaments in antiviral treatment of hepatitis C.

Reference

[1]Zeuzem,S.,Soriano,V.,Asselah,T.,etc.Faldaprevir and deleobuvir for HCV genotype 1 infection[J].2013,369(7).
[2]Firpi,R.,Duvoux,C.,Levy,G.,etc.Recurrent hepatitis C virus infection post liver transplantation: Impact of choice of calcineurin inhibitor[J].2013,26(4).
[3].EASL Clinical Practice Guidelines: management of hepatitis C virus infection.[J].2011,55(2).
[4]THOMAS KUNTZEN,JOERG TIMM,MELANIE A. BACA,etc.Spontaneous Control of HCV Is Associated With Expression of HLA-B*57 and Preservation of Targeted Epitopes[J].2011,140(2).
[5]Yumiko, Nagao,Michio, Sata.A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: association study with mutations in the core and NS5A region of hepatitis C virus.[J].2012,12.
[6]Masahiro Kobayashi,Kazuaki Chayama,Yusuke Kawamura,etc.Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.[J].2012,47(5).
[7]Yang HY,Rhodes SL,Yang K,etc.A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection[J].2007,104(26).
[8]Burroughs,M.H.,Poordad,F.,Bacon,B.,etc.Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis[J].2013,58(3).
[9]Lawitz EJ,Shiffman ML,McHutchison JG.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.[J].2009,361(6).
[10]Murayama,A.,Matsumura,T.,Wakita,T.,etc.25-hydroxyvitamin D 3 suppresses hepatitis C virus production[J].2012,56(4).
[11]Katja Nitschke,Alejandro Barriga,Julia Schmidt,etc.HLA-B∗27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope[J].2014,60(1).
[12]Saurabh, Kedia,Rohit, Goyal,Vivek, Mangla,etc.Splenectomy in cirrhosis with hypersplenism: improvement in cytopenias, Child's status and institution of specific treatment for hepatitis C with success.[J].1900,11(6).
[13]Nour,Z.A.,ElRaziky,M.,Nassar,Y.H.,etc.Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children[J].2013,57(2).
[14]Maehara Y,Fukuhara T,Taketomi A,etc.Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation.[J].2010,52(5).
[15]Iacobellis A,Perri F,Valvano MR,etc.Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis.[J].2011,9(3).
[16].HCV NS5A and IRF9 compete for CypA binding[J].2013,58(1).
[17]Sugimachi,Tomikawa M,Akahoshi T.Laparoscopic splenectomy may be a superior supportive intervention for cirrhotic patients with hypersplenism.[J].2010,25(2).
[18]Bruno S,Shiffman ML,Roberts S.Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.[J].2010,51(2).
[19]Alric,L.,Feray,C.,Marcellin,P.,etc.Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890[J].2013,59(3).
[20]McNally,J.,Younossi,Z.,Sheikh,A.M.,etc.Sofosbuvir for previously untreated chronic hepatitis C infection[J].2013,368(20).
[21]Suzuki, Yoshiyuki,Saitoh, Satoshi,Sezaki, Hitomi,etc.Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis[J].2013,56(1).
[22]Kyung Hoon, Kim,Byoung Kuk, Jang,Woo Jin, Chung,etc.Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.[J].2011,17(3).
[23]Pinta,A.,Rouanet,S.,Vray,M.,etc.Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: The Hepatys French cohort (2003-2007)[J].2012,17(1).
[24]Craxì,A.,Calvaruso,V..2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines[J].2012,32(Suppl.1).
[25]Giannini EG,Basso M,Savarino.Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.[J].2009,266(6).
[26]Dessein A,Penaranda G,Argiro L,etc.A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.[J].2011,23(10).
[27]K. Patterson,W. J. Cash,M. E. Callender.Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients[J].2010,17(4).
[28]Filomena Morisco,Rocco Granata,Tommaso Stroffolini,etc.Sustained virological response: A milestone in the treatment of chronic hepatitis C[J].2013,(18).